­
­
­
­

Inventi Impact: Psychiatry & Neurology

Articles

  • Inventi:hpyn/24393/17
    Leptomeningeal Contrast Enhancement Is Associated with Disability Progression and Grey Matter\nAtrophy in Multiple Sclerosis
    01-Jan-1970 Research 2018 : January - March
    Gleb Makshakov, Evgeniy Magonov, Natalia Totolyan, Vladimir Nazarov, Sergey Lapin, Alexandra Mazing, Elena Verbitskaya, Tatiana Trofimova, Vladimir Krasnov, Maria Shumilina, Alexander Skoromets, Evgeniy Evdoshenko

    Leptomeningeal contrast enhancement (LMCE) on magnetic resonance imaging (MRI) is a newly recognized possible biomarker\nin multiple sclerosis (MS), associated with MS progression and cortical atrophy. In this study, we aimed to assess the prevalence of\nLMCE foci and their impact on neurodegeneration and disability. Materials. 54 patients with MS were included in the study. LMCE\nwere detected with a 3 Tesla scanner on postcontrast fluid-attenuated inversion-recovery (FLAIR) sequence. Expanded Disability\nStatus Scale (EDSS) score, number of relapses during 5 years from MS onset, and number of contrast-enhancing lesions on T1\nweighted MRI were counted. Results. LMCE was detected in 41% (22/54) of patients. LMCE-positive patients had longer disease\nduration (

    How to Cite this Article
    CC Compliant Citation: Gleb Makshakov, Evgeniy Magonov,\nNatalia Totolyan, et al., â??Leptomeningeal Contrast Enhancement\nIs Associated with Disability Progression and Grey Matter\nAtrophy in Multiple Sclerosis,â? Neurology Research\nInternational, vol. 2017, Article ID 8652463, 7 pages, 2017.\ndoi:10.1155/2017/8652463, https://creativecommons.org/\nlicenses/by/4.0/.
    Download Full Text